News&Events
-
July 30,2026
TrueLab Biopharmaceutical Announces Completion of Enrollment for the Phase 1 SAD Part of TL-003
China – July 30, 2026, TrueLab Biopharmaceutical, an immunology-driven innovator leveraging a proprietary, AI-powered R&D platform to develop transformative therapies for immune-mediated inflammatory diseases, today announced the completion of enrollment for the Phase 1 SAD Part (NCT07526519) of TL-003, an anti-TL1A×IL23p19 bispecific antibody.
Learn More
-
June 22,2026
TrueLab Biopharmaceutical Announces License Agreement with Bionyra Pharma Valued up to $985 Million
China – June 22, 2026, TrueLab Biopharmaceutical, an immunology-driven innovator leveraging a proprietary, AI-powered R&D platform to develop transformative therapies for immune-mediated inflammatory diseases, today announced that it has entered into an exclusive license agreement with Bionyra Pharma, a newly launched clinical-stage biopharmaceutical company, for TL-001, an anti-TL1A monoclonal antibody, and TL-003, a TL1A × IL-23p19 bispecific antibody.
Learn More